Items where authors include "Mori, K."

Article

Harrison, F.A., Aird, J., Civano, F. et al. (41 more authors) (2016) The NuSTAR Extragalactic Surveys: The Number Counts of Active Galactic Nuclei and the Resolved Fraction of the Cosmic X-Ray Background. Astrophysical Journal, 831 (2). 185. ISSN 0004-637X

Ando, K., Heymann, M.F., Stresing, V. et al. (3 more authors) (2013) Current Therapeutic Strategies and Novel Approaches in Osteosarcoma. Cancers, 5 (2). pp. 591-616. ISSN 2072-6694

Ando, K., Mori, K., Verrecchia, F. et al. (3 more authors) (2012) Molecular Alterations Associated with Osteosarcoma Development. Sarcoma, 2012. 523432. ISSN 1357-714X

Ando, K., Mori, K., Corradini, N. et al. (2 more authors) (2011) Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opinion on Pharmacotherapy, 2 (12). pp. 285-292. ISSN 1465-6566

Mori, K., Ando, K., Heymann, D. orcid.org/0000-0001-7777-0669 et al. (1 more author) (2009) Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells? Histology and Histopathology, 24 (2). pp. 235-242. ISSN 0213-3911

Mori, K., Blanchard, F., Charrier, C. et al. (6 more authors) (2008) Conditioned media from mouse osteosarcoma cells promote MC3T3-E1 cell proliferation using JAKs and PI3-K/Akt signal crosstalk. Cancer Science, 99 (11). pp. 2170-2176. ISSN 1347-9032

Brounais, B., Chipoy, C., Mori, K. et al. (7 more authors) (2008) Oncostatin M induces bone loss and sensitizes rat osteosarcoma to the antitumor effect of midostaurin in vivo. Clinical Cancer Research, 14 (17). pp. 5400-5409. ISSN 1078-0432

Ando, K., Mori, K., Rédini, F. et al. (1 more author) (2008) RANKL/RANK/OPG: key therapeutic target in bone oncology. Current Drug Discovery Technologies, 5 (3). pp. 263-268. ISSN 1570-1638

Mori, K., Ando, K. and Heymann, D. orcid.org/0000-0001-7777-0669 (2008) Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases. Expert Review of Anticancer Therapy, 8 (2). pp. 151-159. ISSN 1473-7140

Mori, K., Berreur, M., Blanchard, F. et al. (5 more authors) (2007) Receptor activator of nuclear factor-kappa B ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncology Reports, 18 (6). pp. 1365-1371. ISSN 1021-335X

Mori, K., Le Goff, B., Charrier, C. et al. (3 more authors) (2007) DU145 human prostate cancer cells express functional receptor activator of NF kappa B: New insights in the prostate cancer bone metastasis process. Bone , 40 (4). pp. 981-990. ISSN 8756-3282

Mori, K., Le Goff, B., Berreur, M. et al. (11 more authors) (2007) Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. The Journal of Pathology, 211 (5). pp. 555-562. ISSN 0022-3417

Mori, K., Redini, F., Gouin, F. et al. (2 more authors) (2006) Osteosarcoma: Current status of immunotherapy and future trends (Review). Oncology Reports, 15 (3). pp. 693-700. ISSN 1021-335X

Wittrant, Y., Lamoureux, F., Mori, K. et al. (4 more authors) (2006) RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. International Journal of Oncology, 28 (1). pp. 261-269. ISSN 1019-6439

Theoleyre, S., Mori, K., Cherrier, B. et al. (4 more authors) (2005) Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. BMC Cancer, 5. 123. ISSN 1471-2407